Hypothesis: can N-acetylcysteine be beneficial in Parkinson's disease?

Life Sci. 1999;64(15):1253-7. doi: 10.1016/s0024-3205(98)00472-x.

Abstract

Based on the finding of decreased mitochondrial complex I activity in the substantia nigra of patients with Parkinson's disease, we propose that the consequent reduction of ATP synthesis and increased generation of reactive oxygen species may be a possible cause of nigrostriatal cell death. Since sulfhydryl groups are essential in oxidative phosphorylation, thiolic antioxidants may contribute to the preservation of these proteins against oxidative damage. In the present paper, we hypothesize that treatment with a sulfur-containing antioxidant such as N-acetylcysteine may provide a new neuroprotective therapeutic strategy for Parkinson's disease.

Publication types

  • Review

MeSH terms

  • Acetylcysteine / therapeutic use*
  • Adenosine Triphosphate / metabolism
  • Corpus Striatum / metabolism
  • Corpus Striatum / pathology
  • Humans
  • Mitochondria / enzymology
  • Models, Neurological
  • NAD(P)H Dehydrogenase (Quinone) / metabolism
  • Neuroprotective Agents / therapeutic use
  • Oxidative Phosphorylation
  • Parkinson Disease / drug therapy*
  • Parkinson Disease / metabolism*
  • Parkinson Disease / pathology
  • Reactive Oxygen Species
  • Substantia Nigra / metabolism
  • Substantia Nigra / pathology

Substances

  • Neuroprotective Agents
  • Reactive Oxygen Species
  • Adenosine Triphosphate
  • NAD(P)H Dehydrogenase (Quinone)
  • Acetylcysteine